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Abstract
Background
In epidemiological studies, continuous measures of asthma severity should be used to
catch the heterogeneity of phenotypes. This study aimed at developing and validating con-
tinuous measures of asthma severity in adult patients with ever asthma from the general
population, to be used in epidemiological studies.
Methods
Respiratory symptoms, anti-asthmatic treatment and lung function were measured on 520
patients with ever asthma aged 20–64 years from the general Italian population (GEIRD
study; 2007/2010). The variables that represent the same dimension of asthma severity
were identified through an exploratory factor analysis and were summarized through a multi-
ple factor analysis.
Results
Only respiratory symptoms and anti-asthmatic treatment were summarized in a continuous
score (STS). STS ranges from 0 (no symptoms/treatment) to 10 (maximum symptom fre-
quency and treatment intensity). STS was positively correlated with the Global Initiative for
Asthma classification of asthma severity computed on the 137 cases with a doctor’s diagno-
sis (Spearman’s coefficient = 0.61, p-value<0.0001) (concurrent validity). Furthermore,
using a cohort of 1,097 European asthmatics (ECRHS II study; 1999/2002), increasing STS
levels at baseline (1991/1993) were positively associated with long-term outcomes (hospi-
talization and lost workdays for breathing problems, asthma attack frequency and use of
asthma controllers) (predictive validity). Finally, the STS scores computed from the GEIRD
and ECRHS II data were comparable (Lin’s coefficient = 0.95, p-value<0.0001) (replication
analysis).
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Conclusions
STS is a valid and replicable measure of asthma severity in adults, which could be used in
association studies.
Introduction
Asthma represents a global health problem because of its high morbidity [1] and the heavy
socio-economic burden [2–5].
The identification of the level of asthma severity is crucial for treatment decisions in clinical
practice and for patients’ characterization in epidemiological studies. In fact, asthma is not a
single disease and its severity is characterized by different phenotypes that may result from dif-
ferent risk factors [6–8]. However, defining ’asthma severity’ is not an easy task, mainly
because of its heterogeneity and the lack of a worldwide consensus on its definition [9].
According to the 2002 and 2004 Global Initiative for Asthma (GINA) guidelines [10], a cate-
gorical classification of asthma severity, which is based on symptom frequency, lung function
and treatment intensity has been used in several epidemiological studies [11–16]. The choice
of this composite measure is justified by the fact that no single measures could accurately
reflect heterogeneous phenotypes of asthma severity. However, continuous outcomes should
be used for epidemiological purposes because any categorical classification of disease severity
is biologically unsatisfactory for the majority of chronic diseases [17]. Moreover, individual
pathophysiological characteristics of asthma severity are mainly measured on continuous or
ordinal scales [9]. In addition, recognizing the nature of asthma as a continuum increases the
power of a statistical analysis [18] and has the potential to reduce bias in the evaluation of risk
factors for asthma [19].
The present study is aimed at developing and validating continuous measures of asthma
severity that summarize the individual information on lung function, symptom frequency and
treatment intensity in adult patients with ever asthma from the general population, to be used
in epidemiological studies. To fulfill this purpose, the data from the Gene Environment Inter-
actions in Respiratory Diseases (GEIRD) study were used.
Methods
Design of the GEIRD study
GEIRD (www.geird.org) is an ongoing multicentre, (multi)case-control study on respiratory
health [20], which includes more than 20,000 subjects who were randomly selected from the
general population in seven Italian centres (Ancona, Pavia, Salerno, Sassari, Terni, Turin and
Verona). The cases of asthma, chronic obstructive pulmonary disease (COPD), chronic bron-
chitis and rhinitis, and the subjects without respiratory symptoms (controls) were identified
through a two-stage screening process. In the first stage (2007–2010), the participants were
administered a screening questionnaire on respiratory health. In the second stage (2008-ongo-
ing), all the responders to the screening questionnaire with symptoms suggestive of asthma,
COPD or chronic bronchitis, and a random sample of those with symptoms suggestive of rhi-
nitis or without respiratory symptoms, were invited to undergo a detailed clinical interview,
lung function and laboratory tests for accurate phenotyping. Ethics approval was obtained
from the appropriate ethics committee (“Comitato Etico per la Sperimentazione dell’Azienda
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Ospedaliera Istituti Ospitalieri di Verona”). All participants were fully informed about all the
aspects of the research project and they gave written informed consent.
Cases of asthma
The subjects were defined as having asthma if they had reported at least one of the two follow-
ing conditions at the clinical examination:
1. ever asthma;
2. asthma-like symptoms [wheezing, nocturnal tightness in the chest, shortness of breath
(SoB) following strenuous activity, SoB at rest, SoB at night time] or anti-asthmatic treat-
ment in the past 12 months at the clinical interview, and if they had fulfilled at least one of
the following spirometric criteria:
a. being positive to the methacholine challenge test with a <1 mg dose producing a 20%
fall in FEV1;
b. having a pre-bronchodilator airflow obstruction {FEV1/FVC<70% or<Lower Limit of
Normal for FEV1/FVC according to Quanjer [21]} and a positive reversibility test
(increase in FEV1 >12% and>200 ml with respect to pre-bronchodilator FEV1 after 400
mcg of salbutamol);
c. having pre- but not post-bronchodilator airflow obstruction, and a post-bronchodilator
FEV180% predicted [21].
At the time of the present analysis, only the data on the patients recruited in the Pavia, Sas-
sari, Turin and Verona centres were available. The screening questionnaire was mailed to
17,084 eligible subjects (GEIRD-stage 1; 2007–2010) in these centres. Among the responders
(response rate: 59.4%), 4,792 subjects were invited for further clinical investigations (GEIRD-
stage 2; 2008–2010). Among the 1,640 subjects who were phenotyped, 577 subjects were classi-
fied as cases of asthma (Fig 1).
Computation of asthma severity scores
Asthma severity scores were devised through a two-step procedure, which was carried out on
the 520 cases of asthma (out of the 577 cases identified in the four centres) with complete
information on disease severity (respiratory symptoms, lung function and anti-asthmatic
treatment).
Step 1. An exploratory factor analysis (EFA) [22] was performed on 11 variables (listed in
Table 1) in order to identify the subset of variables representing the same dimension (factor)
of disease severity. This model is based on the assumption that the symptom, treatment and
lung function variables are correlated through some unobservable factors. The values of each
variable were ordered coherently with an increasing level of disease severity. EFA was based
on the mixed correlation matrix between each pair of variables [23], i.e. the polychoric correla-
tion between two ordinal variables, the tetrachoric correlation between two dichotomous vari-
ables, the Pearson moment correlation between two continuous variables, and the polyserial
correlation if one variable is categorical and the other one is continuous.
Factors were retained at EFA if the eigenvalue was greater than the mean of eigenvalues and
by means of the break in the scree plot (eigenvalues vs. factors). The uniqueness (i.e. propor-
tion of variance in a given variable that is not due to the extracted common factor) was used to
identify the variables that were poorly correlated with the extracted factors. The Kaiser-Meyer-
Olkin (KMO) measure was used for assessing the adequacy of the fitted model. The variables
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with a KMO values <0.7 were excluded from the later dimensionality reduction procedure
(MFA).
Step 2. A multiple factor analysis (MFA) [24] was performed on the subset of variables
representing each dimension of asthma severity (identified at EFA) in order to estimate the
weights to be used for computing the corresponding individual score. In MFA, the symptom,
treatment and lung function variables were grouped in three different sets. For each dimension
of asthma severity, the individual scores were obtained as the weighted linear combination of
the variables included in MFA (Methods section in S1 File). All variables were analyzed on the
quantitative scale. Any component that had the eigenvalue greater than the mean of the eigen-
values was retained. Moreover, the break in the scree plot was used to retain components. A
bootstrap procedure with 50,000 replications was used to obtain a stable solution for eigenval-
ues, weights and scores.
Concurrent validity
Spearman’s coefficients were computed to evaluate the concordance between the identified
scores and a categorical classification of asthma severity, which was defined according to the
GINA guidelines [25] on the 137 cases who had reported a doctor’s diagnosis of asthma and
complete information on the GINA classification of asthma severity.
Predictive validity
The data from the European Community Respiratory Health Survey (ECRHS), which is an
international, population based cohort study on respiratory health in subjects aged 20–44
years at the time of recruitment (ECRHS I; 1991–1993) [26], were used to evaluate the ability
of the identified scores to predict future events. The predictive validity was verified on the
subjects with ever asthma from 26 centres, who were identified at the ECRHS I and had
Fig 1. Flow chart of the GEIRD study in the Pavia, Sassari, Turin and Verona centres, and selection of
the cases of asthma.
https://doi.org/10.1371/journal.pone.0177538.g001
Assessment of asthma severity in adults with ever asthma: A continuous score
PLOS ONE | https://doi.org/10.1371/journal.pone.0177538 May 18, 2017 4 / 15
participated in the ECRHS II (1999–2002), by evaluating the association between the scores
computed at the ECRHS I (using the weights estimated from the GEIRD data) and the follow-
ing long-term outcomes measured at the ECRHS II: (i) having at least one emergency depart-
ment visit and/or hospital admission for breathing problems during the follow-up, (ii) number
of asthma attacks in the past 12 months, (iii) use of asthma controllers in the past 12 months,
and (iv) having lost at least one working day due to breathing problems in the past 12 months.
The association between the ECRHS-scores and each outcome was evaluated by using two-
level regression models, with subjects (1st level units) nested into centres (2nd level units). The
hospitalization Rate Ratios (RR) were computed by using two-level Poisson regression models
by setting the person-years equal to half the length of the follow-up in the case of at least one
Table 1. Coding and definition of the candidate variables.
Name Definition Coding†
Wheezing “How many times have you had wheezing or whistling in the last 12 months?” 0 (ever)
1 (sometimes)
2 (at least once a week)
Asthma attacks “How many attacks of asthma have you had in the last 12 months?” 0 (none)
1 (1–11 attacks)
2 (12 attacks)
Tightness in chest “Have you woken up with a feeling of tightness in your chest at any time in the last 12
months?”
0 (no)
1 (yes)
SOB at rest “Have you had an attack of shortness of breath that came on during the day when you were at
rest at any time in the last 12 months?”
0 (no)
1 (yes)
SOB after strenuous
activity
“Have you had an attack of shortness of breath that came on following strenuous activity at
any time in the last 12 months?”
0 (no)
1 (yes)
SOB at night time “Have you been woken by an attack of shortness of breath at any time in the last 12 months?” 0 (no)
1 (yes)
Chronic bronchitis Cough or phlegm on most days for a minimum of three months a year and for at least two
successive years.
0 (no)
1 (yes)
Worsening of respiratory
symptoms
“In the last 12 months, have you had any episodes/times when your symptoms (cough,
phlegm, shortness of breath) were a lot worse than usual?” or “In the last 12 months have you
visited a hospital casualty department or emergency room (for breathing problems)?” or “In
the last 12 months, have you spent a night in hospital (for breathing problems)?”
0 (no)
1 (yes to at least one of the
three questions)
Treatment Intensity of anti-asthmatic treatment in the past 12 months. 0 (no treatment)
1 (GINA step 1- only
relievers)*
2 (GINA step 1—controllers)
**
3 (GINA steps2)***
FEV1% predicted Pre-bronchodilator FEV1% predicted (continuous)
FEV1/FVC Pre-bronchodilator FEV1/FVC (continuous)
† all variables were ordered coherently with an increasing level of asthma severity, i.e. the higher the level of the observed variables, the higher the value of
asthma severity.
* GINA step 1—only relievers: treatment with short-acting β2-agonists and/or anticholinergic and/or ketotifen without controllers in the past 12 months.
** GINA step 1—controllers with/without taking relievers: discontinuous treatment with Inhaled glucocorticosteroids (ICS) or Cromones or Oral
Methylxanthines or Leukotriene modifiers or ICS & Long-acting β2-agonists or ICS & Methylxanthines or ICS & Leukotriene modifiers with/without taking
relievers in the past 12 months.
*** GINA steps2: treatment with ICS (daily) or Cromones (daily) or Oral Methylxanthines (daily) or Leukotriene modifiers (daily) or ICS & Long-acting
β2-agonists (daily) or ICS & Methylxanthines (daily) or ICS & Leukotriene modifiers (daily) or Oral glucocorticosteroids or anti-IgE or Injective
Corticosteroids with/without taking relievers in the past 12 months.
https://doi.org/10.1371/journal.pone.0177538.t001
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hospitalization. The adjusted Ratios of Expected number of asthma attacks (RE) were com-
puted by using a two-level negative binomial regression model. We chose a negative binomial
model because of the over-dispersed distribution of the “number of asthma attacks” variable
(Pearson’s moment coefficient of skewness = 8.7) and its better fit as compared to the Poisson
model (likelihood ratio test, p-value<0.0001). The association of the ECRHS-scores with the
remaining outcomes was measured through the adjusted Ratio of Expected values (RE)
obtained by means of a two-level Poisson regression model. All the regression models had a
random intercept term at the 2nd level, and the ECRHS-score and potential confounders (gen-
der, age, BMI and smoking habits at baseline) as fixed effects. The 95% confidence intervals
(CIs) were obtained by using a robust variance estimator (Huber-White sandwich estimator).
Replicability
The robustness of the identified scores was verified by testing whether the MFA weights
change when estimated from another, similar population [27]. The data from the subjects with
ever asthma, who were identified at the ECRHS I and had participated in the ECRHS II, were
used. The scores obtained by using the weights from the GEIRD data were compared to the
scores of the same dimension, which were computed by using the weights from a new MFA on
the ECRHS II data. The Lin’s concordance correlation coefficient was used (a value0.80
indicates a good replicability).
The statistical analyses were carried out using STATA, version 13.0, and R version 3.1.0.
Results
Main characteristics of patients
In our sample, the percentage of females was 51.9%, the mean age was 43.0 years (SD, standard
deviation; SD = 9.4) and the median BMI was 24.4 (IQR, interquartile range; IQR = 21.7–27.0)
(Table 2). Ever smokers were predominant (51.4%). About two out of three patients reported
at least one attack of asthma, the presence of at least one asthma-like symptom, the use of anti-
asthmatic treatment, the worsening of symptoms or the use of hospital services in the past 12
months. In addition, 32.5% of these subjects had used anti-asthmatic treatment in the past 12
months, and 15.0% of the 314 asthmatics with available information had reported a not well
controlled disease {i.e. 5-item Asthma Control Questionnaire (ACQ) score [28] less than 20}.
Finally, pre-bronchodilator FEV1% predicted and FEV1/FVC were 102.2 (SD = 14.3) and 78.6
(SD = 7.8) on average, respectively.
Dimensionality reduction procedure
The mixed correlation matrix suggested that there was redundant information in the data and
that the two lung function variables were weakly correlated with the variables regarding respi-
ratory symptoms and anti-asthmatic treatment (Table A in S1 File). Moreover, the EFA identi-
fied one factor that explained 84% of the total variance, whereas this factor explained 5% and
8% of the variance of pre-bronchodilator FEV1% predicted and FEV1/FVC, respectively. In
addition, the model adequacy checking indicates that the lung function variables may not
belong to the extracted factor (Table B and Figure A in S1 File). Therefore, only the 9 variables
regarding symptom frequency and anti-asthmatic treatment intensity represent the same
dimension of asthma severity and were considered in the dimensionality reduction procedure.
The MFA extracted two components that accounted for 41% and 19% of the total variance,
respectively. Only the first MFA component was considered as a score of asthma severity
Assessment of asthma severity in adults with ever asthma: A continuous score
PLOS ONE | https://doi.org/10.1371/journal.pone.0177538 May 18, 2017 6 / 15
because all the weights had the positive sign, as expected for a measure of disease severity
(Table C and Figure A in S1 File).
Symptom frequency and anti-asthmatic Treatment intensity Score (STS)
According to the coding of the variables as reported in Table 1, the equation used to compute
individual STS is the following:
STS ¼ 1:03 ðWheezingÞ þ 0:85 ðAsthma attacksÞ þ 0:48 ðTightness in chestÞ
þ 0:32 ðSOB at restÞ þ 0:46 ðSOB after strenuous activitiesÞ
þ 0:38 ðSOB at night timeÞ þ 0:27 ðChronic bronchitisÞ
þ 0:34 ðWorsening of respiratory symptomsÞ þ 1:33 ðTreatmentÞ:
STS ranges from 0 (no respiratory symptoms and no anti-asthmatic treatment) to 10 (maxi-
mum level of symptom frequency and treatment intensity) on a continuous scale, and it has a
skewed distribution towards low values (Fig 2), which can be approximated to some common
Table 2. Main characteristics of the 520 cases of asthma identified in the GEIRD study.
Main characteristic Sub-characteristic Summary statistics Numerical value
Females % 51.9
Age (years) mean ± sd 43.0 ± 9.4
Smoking habits Never smoker % 48.6
Past smoker 26.0
Current smoker 25.4
BMI median (interquartile range) 24.4 (21.7–27.0)
Wheezing* Never % 60.0
Sometimes 32.7
At least once a week 7.3
Asthma attacks* None % 80.0
1–11 attacks 15.6
 12 attacks 4.4
Tightness in chest* % 21.0
SOB at rest* % 12.1
SOB after strenuous activity* % 23.3
SOB at night time* % 16.0
Chronic bronchitis % 17.7
Worsening of respiratory symptoms* % 15.8
Treatment* None % 64.4
GINA step 1—only relievers 14.0
GINA step 1 –controllers 12.7
GINA steps 2 8.9
Pre-bronchodilator FEV1% predicted mean ± sd 102.2 ± 14.3
Pre-bronchodilator FEV1/FVC mean ± sd 78.6 ± 7.8
ACOS** % 3.1
ACQ 5–19 % 15.0
20–24 38.2
25 46.8
SOB, shortness of breath; ACOS, Asthma-COPD Overlap Syndrome; ACQ, Asthma Control Questionnaire.
* in the past 12 months.
** post-bronchodilator FEV1/FVC <Lower Limit of Normal according to Quanjer (21).
https://doi.org/10.1371/journal.pone.0177538.t002
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parametric distribution, such as a Zero-inflated Gamma. In our sample, STS ranged from 0 to
9.35 (median = 1.20, IQR = 0–3.53) and 33.5% of the 520 patients had a score equal to 0,
because they had reported ever asthma without the presence of respiratory symptoms and
without the use of asthma medications in the past 12 months.
Fig 2. Distribution of the Symptom frequency and anti-asthmatic Treatment intensity Score (STS). Data from the GEIRD study.
https://doi.org/10.1371/journal.pone.0177538.g002
Table 3. Median of the Symptom frequency and anti-asthmatic Treatment intensity Score (STS) according to the GINA classification of asthma
severity. Data from the GEIRD study.
GINA classification* N Median (IQR) p-value
Intermittent 72 3.61 (2.58–4.48) <0.00001†
mild persistent 17 5.17 (4.07–6.59)
moderate persistent 17 5.66 (3.99–6.13)
severe persistent 31 5.99 (5.02–7.70)
IQR, interquartile range.
* GINA classification was calculated on patients with a doctor’s diagnosis of asthma.
† Spearman’s correlation coefficient, which was computed to evaluate the concordance between STS and the GINA classification of asthma severity.
https://doi.org/10.1371/journal.pone.0177538.t003
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Concurrent validity of STS
Among the 137 GEIRD cases with an asthma diagnosis, the individuals who had received daily
controller medications had a significantly lower STS (median = 0.46, IQR = 0–1.86) as com-
pared to both the subjects treated with non-daily controller medications (median = 4.47,
IQR = 3.48–5.47) and the subjects not treated with controller medications (median = 5.87,
IQR = 4.45–7.47) in the past 12 months. Moreover, STS was positively correlated with the
GINA classification of asthma severity (Spearman’s coefficient = 0.61, p-value<0.0001)
(Table 3).
Predictive validity of STS
In the ECRHS cohort, 1,097 subjects with ever asthma had provided complete information on
STS at the ECRHS I and on at least one long-term outcome (Table D in S1 File). We found
that the long-term outcomes were predicted by increased values of STS (Table 4). In particular,
for one-unit increase in STS, the risk of hospitalization for breathing problems during the
9-year follow-up (between the ECRHS I and II) raised by 31% and the expected number of
asthma attacks in the past 12 months at ECRHS II raised by 46%. Furthermore, at ECRHS II,
the expected number of subjects with at least one working day lost due to breathing problems
in the past 12 months increased by 25%; the same figure was observed for the use of controller
medications.
Replicability of STS
In the ECRHS cohort, 1,327 subjects with ever asthma had provided complete information on STS
at the ECRHS II (Table D in S1 File). The STS scores computed from the GEIRD and ECRHS II
data were comparable (Fig 3), the Lin’s coefficient being equal to 0.95 (p-value<0.0001), which
indicates an excellent replicability.
Discussion
The main results of the present study are the following:
Table 4. Association between the Symptom frequency and anti-asthmatic Treatment intensity Score
(STS) at baseline (1991–1993) and long-term outcomes at the end of follow-up (1999–2001). Data from
the ECRHS study.
Long-term outcomes
(measure of association)
Estimate* [95%CI] p-value
Hospitalization** (RR)† 1.31 [1.24, 1.39] <0.001
N. of asthma attacks‡ (RE)§ 1.46 [1.30, 1.63] <0.001
Use of controller drugs‡ (RE)§ 1.25 [1.21, 1.29] <0.001
At least one working day lost‡ (RE)§ 1.25 [1.16, 1.35] <0.001
RR, adjusted rate ratio; RE, adjusted ratio of expected values.
* for one-unit increase in STS.
** at least one emergency department visit and/or hospital admission for breathing problems during the 9-yr
follow-up (between the ECRHS I and II).
† adjusted for gender, age, BMI and smoking habits at ECRHS I.
‡ in the past 12 months at ECRHS II.
§ adjusted for gender, age, BMI and smoking habits at baseline, and length of the follow-up.
https://doi.org/10.1371/journal.pone.0177538.t004
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1. Lung function variables were weakly correlated with respiratory symptoms and anti-asth-
matic treatment in adults. Therefore, lung function, symptom and treatment variables
should not be summarized in one dimensional score of asthma severity.
2. A continuous measure of asthma severity has been devised, which summarizes the fre-
quency of respiratory symptoms and the intensity of anti-asthmatic treatment. This score
has been proved to be a valid measure of asthma severity in adults and it seems to be repli-
cable in adult populations from different European countries. Moreover, a parametric
modelling approach can be adopted in analyzing this score.
Different dimensions of asthma severity
We investigated which scores could summarize the different dimensions of asthma severity
in adult patients, i.e. the frequency of respiratory symptoms, the intensity of anti-asthmatic
treatment and lung function. Since the list of symptoms described in the GINA guidelines is
claimed to be incomplete [29], a larger set of respiratory symptoms was considered in the pres-
ent analyses.
Fig 3. Relationship between the Symptom frequency and anti-asthmatic Treatment intensity Score (STS) computed by using the weights
from the GEIRD data (horizontal axis) and STS computed by using the weights from the ECRHS II data (vertical axis).
https://doi.org/10.1371/journal.pone.0177538.g003
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In order to create summary measures of asthma severity, the redundancy of information in
the considered variables is essential. A correlation between respiratory symptoms and lung
function is expected because wheezing, tightness in the chest and cough are most likely to be
obstructive symptoms. However, other respiratory symptoms, such as shortness of breath, prob-
ably reflect non-obstructive dyspnea [29]. We found a weak correlation between our set of
symptom and anti-asthmatic treatment variables, and the two lung function measures. This fact
is in agreement with the results from other studies, which have shown a modest association
between lung function decline and increased respiratory symptoms [30–31]. In addition, only
5% and 8% of the variance of FEV1% predicted and FEV1/FVC, respectively, is explained by a
common, unobserved factor found in the EFA analysis. When EFA was repeated without the
lung function measures, the unobserved factor explains more than 84% of the common variance
of the symptom and treatment variables. Therefore, combining respiratory symptoms and lung
function variables into a single score is not supported by our data, as found in another study in
which lung function had only a small impact on the categorization of asthma severity [32].
MFA helps to remove the redundant information in symptom and treatment variables. We
identified two components that explain a high proportion of the total variance (Table C and
Figure A in S1 File). The first component can be interpreted as a measure of asthma severity in
adult subjects because all weights connected to the frequency of respiratory symptoms and the
intensity of anti-asthmatic treatment have a positive sign. The second component separates
the patients with the maximum intensity of treatment but no symptoms, from the individuals
with no treatment but the maximum frequency of symptoms, because the weights of the treat-
ment and symptom variables have an opposite sign. Therefore, the second component should
be a measure of asthma control. In fact, recent guidelines report that asthma control refers to
the extent to which the disease manifestations have been reduced or removed by treatment
[33]. Despite being different clinical constructs, asthma severity and asthma control are re-
lated. In fact, we found a weak negative correlation between STS and the 5-item ACT score
(Pearson’s coefficient = -0.47, p-value<0.0001).
STS and asthma severity
In several epidemiological studies, measures of asthma severity are computed as the sum of
symptoms (i.e. equal weights are assigned to each component variable) [34–35]. STS makes it
possible to weight the contribution to asthma severity of each symptom and anti-asthmatic
treatment in respect to these simple scores. The self-reported intensity of anti-asthmatic treat-
ment has the highest weight in STS. Asthma medications reflect the physician assessment of a
patient’s underlying severity. In fact, the utilization of a categorical classification of treatment
intensity as an approximate index of asthma severity is suggested in population studies where
clinical data on disease severity are lacking [36]. Among respiratory symptoms, wheezing has
the highest weight in the STS equation, followed by asthma attacks. In fact, different studies
have shown that wheezing (alone or in combination with other symptoms) is the most com-
mon physical finding in adult asthma [37–39].
The use of continuous scores is recommended in epidemiological studies [18]. In fact,
asthma symptoms exist as a continuum in a population [19], and data supporting the existence
of one (or more) cut-off points that discriminate subjects into severe (or different levels of
severity) and not-severe asthma, are somewhat arbitrary. Furthermore, continuous measures
make it possible to increase the power in association analyses, and this fact is particularly
important when the sample size is small [19]. Moreover, the power of an association analysis
further increases by using a parametric modelling approach for STS, since it is possible to
assume a known theoretical distribution of the score [40].
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STS is a useful measure of asthma severity in population studies because its validity and rep-
licability, which are two fundamental characteristics of any measurement procedure [41], were
demonstrated. Concurrent validity was proved by evaluating the relation between STS and an
alternative classification of asthma severity, based on the GINA guidelines. However, the pre-
dictive validity is a stronger criterion for validating a measuring instrument [42], as compared
to the concurrent validity, because a gold standard for asthma severity does not currently exist.
Accordingly, strong positive relationships were observed between an increasing level of STS
and the worsening of different long-term outcomes. Moreover, we found a very small variation
in the STS weights, when they were computed by using the data from geographically and cul-
turally different European populations (ECRHS). This variation in STS weights (Fig 3) can be
attributed to a combination of differences between the clinical questionnaires used in the
GEIRD and ECRHS II studies (see “Strengths and weakness of the study” paragraph) and
between the characteristics of the GEIRD and ECRHS populations (Table D in S1 File).
Lung function and asthma severity
Pre-bronchodilator FEV1% predicted and FEV1/FVC are used as objective measures of respi-
ratory health. The use of FEV1 is recommended to determine the severity of airflow obstruc-
tion, and FEV1/FVC to confirm an obstructive defect [43]. Lung function measurements are
important because patients, especially those who have frequent exacerbations, could have a
poor perception of the severity of their symptoms [44]. In addition, people who have a seden-
tary lifestyle might not experience bothersome symptoms even if they have low lung function
[33]. However, lung function tests alone are not sufficient, and the understanding of patient’s
symptom severity is equally important.
Strengths and weakness of the study
The main strength of the present analysis is that our cases of asthma underwent an accurate
phenotyping by means of an extended clinical interview and lung function tests [20]. More-
over, the data were collected in patients who had been identified from the general population,
rather than from clinically selected groups, which should guarantee that our sample encom-
passes a wide spectrum of disease severity.
A few caveats should be taken into account when interpreting our results. Although our
patients were identified from large samples of subjects from the general population, the num-
ber of asthma cases was relatively small. However, our estimates do not change when com-
puted from a larger number of patients selected from the European population. There are
some differences between the clinical questionnaires used in the GEIRD and ECRHS II stud-
ies. In particular, in the ECRHS II questionnaire, “wheezing” and “worsening of respiratory
symptoms” variables refer to the “presence of wheezing or whistling in the past 12 months”
and “having at least one emergency department visit or hospital admission for breathing prob-
lems in the past 12 months”, respectively. Finally, the age range of the GEIRD (20–64 yrs) and
ECRHS (28–57 yrs) cases of asthma are not perfectly overlayable.
Conclusions
Lung function, symptom and treatment variables seem to represent different dimensions of
asthma severity in adults with ever asthma. Therefore, we propose STS as a continuous mea-
sure of the frequency of respiratory symptoms and the intensity of anti-asthmatic treatment,
to be used in epidemiological studies. This score has been proved to be a valid and replicable
measure of asthma severity and its distribution can be approximated to some known paramet-
ric distribution, such as a Zero-inflated Gamma.
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